Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study

被引:243
作者
Abbasi, Seyed-Hesameddin [2 ,3 ]
Hosseini, Fahimeh [3 ]
Modabbernia, Amirhossein [1 ]
Ashrafi, Mandana [1 ]
Akhondzadeh, Shahin [1 ]
机构
[1] Univ Tehran Med Sci, Psychiat Res Ctr, Roozbeh Hosp, Tehran 13337, Iran
[2] Univ Tehran Med Sci, Tehran Heart Ctr, Tehran 13337, Iran
[3] NIOC Cent Hosp, Iranian Petr Ind Hlth Res Inst, Family Hlth Res Ctr, Tehran, Iran
关键词
Add-on; Celecoxib; COX-2; inhibitor; IL-6; Major depressive disorder; Sertraline; INFLAMMATORY RESPONSES; INHIBITOR CELECOXIB; ADJUNCTIVE THERAPY; COX-2; INHIBITORS; CONTROLLED TRIAL; OLDER-ADULTS; RAT MODEL; SCHIZOPHRENIA; CYCLOOXYGENASE-2; INTERLEUKIN-6;
D O I
10.1016/j.jad.2012.03.033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: It has been proposed that the mechanism of the antidepressant effect of celecoxib is linked to its anti-inflammatory action and particularly its inhibitory effect on proinflammatory cytokines (e. g. interleukin-6(IL-6)). We measured changes in serum IL-6 concentrations and depressive symptoms following administration of celecoxib in patients with major depressive disorder (MDD). Methods: In a randomized double-blind placebo-controlled study, 40 patients with MDD and Hamilton Depression Rating Scale-17 items (Ham-D) score >= 18 were randomly assigned to either celecoxib (200 mg twice daily) or placebo in addition to sertraline (200 mg/day) for 6 weeks. Outcome measures were serum IL-6 concentrations at baseline and week 6, and Ham-D scores at baseline and weeks 1, 2, 4, and 6. Results: The celecoxib group showed significantly greater reduction in serum IL-6 concentrations (mean difference (95%CI)=0.42(0.30 to 0.55) pg/ml, t(35)=6.727, P<0.001) as well as Ham-D scores (mean difference (95%CI)=3.35(1.08 to 5.61), t(38)=2.99, P=0.005) than the placebo group. The patients in the celecoxib group experienced more response (95%) and remission (35%) than the placebo group (50% and 5%, P=0.003 and 0.04 respectively). Baseline serum IL-6 levels were significantly correlated with baseline Ham-D scores (r=0.378, P=0.016). Significant correlation was observed between reduction of Ham-D scores and reduction of serum IL-6 levels at week 6 (r=0.673, P<0.001). Limitations: We did not measure other inflammatory biomarkers. Conclusions: We showed that the antidepressant activity of celecoxib might be linked to its capability of reducing IL-6 concentrations. Moreover, supporting previous studies we showed that celecoxib is both safe and effective as an adjunctive antidepressant (Registration number: IRCT138903124090N1). (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:308 / 314
页数:7
相关论文
共 51 条
  • [1] DOUBLE-BLIND RANDOMIZED PARALLEL-GROUP CLINICAL TRIAL OF EFFICACY OF THE COMBINATION FLUOXETINE PLUS MODAFINIL VERSUS FLUOXETINE PLUS PLACEBO IN THE TREATMENT OF MAJOR DEPRESSION
    Abolfazli, Roya
    Hosseini, Mahdi
    Ghanizadeh, Ahmad
    Ghaleiha, Ali
    Tabrizi, Mina
    Raznahan, Maedeh
    Golalizadeh, Mousa
    Akhondzadeh, Shahin
    [J]. DEPRESSION AND ANXIETY, 2011, 28 (04) : 297 - 302
  • [2] Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
    Akhondzadeh, Shahin
    Tabatabaee, Maryam
    Amini, Homayoun
    Abhari, Seyed Ali Ahmadi
    Abbasi, Seyed Hesamedin
    Behnam, Behnaz
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) : 179 - 185
  • [3] CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL
    Akhondzadeh, Shahin
    Jafari, Sara
    Raisi, Firoozeh
    Nasehi, Abbas Ali
    Ghoreishi, Aboulfazl
    Salehi, Bahman
    Mohebbi-Rasa, Soodeh
    Raznahan, Maedeh
    Kamalipour, Abbas
    [J]. DEPRESSION AND ANXIETY, 2009, 26 (07) : 607 - 611
  • [4] Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: Clinical implications
    Alesci, S
    Martinez, PE
    Kelkar, S
    Ilias, I
    Ronsaville, DS
    Listwak, SJ
    Ayala, AR
    Licinio, J
    Gold, HK
    Kling, MA
    Chrousos, GP
    Gold, PW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) : 2522 - 2530
  • [5] Effects of the celecoxib on the acute necrotizing pancreatitis in rats
    Alhan, E
    Kalyoncu, NI
    Ercin, C
    Kural, BV
    [J]. INFLAMMATION, 2004, 28 (05) : 303 - 309
  • [6] IL-6 levels decrease with SSRI treatment in patients with major depression
    Basterzi, AD
    Aydemir, Ç
    Kisa, C
    Aksaray, S
    Tuzer, V
    Yazici, K
    Göka, E
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2005, 20 (07) : 473 - 476
  • [7] The effects of celecoxib augmentation on cytokine levels in schizophrenia
    Bresee, Catherine J.
    Delrahim, Katia
    Maddux, Rachel E.
    Dolnak, Douglas
    Ahmadpour, Oliver
    Rapaport, Mark Hyman
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (03) : 343 - 348
  • [8] PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway
    Bukata, SV
    Gelinas, J
    Wei, XC
    Rosier, RN
    Puzas, JE
    Zhang, XP
    Schwarz, EM
    Song, XYR
    Griswold, DE
    O'Keefe, RJ
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2004, 22 (01) : 6 - 12
  • [9] DEPRESSION, IMMUNOCOMPETENCE, AND PROSTAGLANDINS OF THE E-SERIES
    CALABRESE, JR
    SKWERER, RG
    BARNA, B
    GULLEDGE, AD
    VALENZUELA, R
    BUTKUS, A
    SUBICHIN, S
    KRUPP, NE
    [J]. PSYCHIATRY RESEARCH, 1986, 17 (01) : 41 - 47
  • [10] CARLIN JM, 1987, J IMMUNOL, V139, P2414